{
    "clinical_study": {
        "@rank": "40284", 
        "arm_group": [
            {
                "arm_group_label": "Monster Energy Drink", 
                "arm_group_type": "Experimental", 
                "description": "16oz Monster Energy Original Flavor consume 2 -16oz Monster Energy drinks within 60 minutes"
            }, 
            {
                "arm_group_label": "Active Control", 
                "arm_group_type": "Active Comparator", 
                "description": "16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed as a safety assessment to determine the cardiac and hemodynamic\n      effects of overuse of energy drinks in healthy individuals through ECG, heart rate (HR) and\n      blood pressure measurements.  It will evaluate the use of a consumer available product that\n      is classified as a dietary supplement by the FDA."
        }, 
        "brief_title": "Evaluation of Monster Energy\u00ae Drink Consumption on ECG and Hemodynamic Parameters in Young Healthy Volunteers", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hemodynamic Effects of Energy Drink", 
            "Electrocardiograph Effects of Energy Drinks"
        ], 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male and female, active duty military service members or DoD beneficiaries,\n             who are eligible to receive care at DGMC.\n\n          -  Ages 18-40 years old\n\n          -  Participants must be willing to refrain from caffeine and energy drink use 48 hours\n             prior to study days 1 and 8. They must also refrain from consuming additional\n             caffeine or energy drinks during the 24-hour observation time on days 1-2 and 8-9.\n\n        Exclusion Criteria:\n\n          -  Cardiovascular risk factors: Heart rhythm other than normal sinus, history of atrial\n             or ventricular arrhythmia, family history of premature sudden cardiac death before\n             the age of 60, left ventricular hypertrophy, atherosclerosis, hypertension,\n             palpitations, T-wave abnormalities, baseline corrected QT (QTc) interval greater than\n             440 milliseconds(ms). This will be determined on the ECG obtained during initial\n             screening appointment, and reviewed by cardiologist and through the questionnaire\n             responses of the participant.\n\n          -  Blood pressure at initial screening appointment or at baseline on study Day 1 greater\n             than 140/90\n\n          -  Presence of any known medical condition, confirmed through participant interview.\n             Examples of these are:\n\n          -  Hypertension\n\n          -  Thyroid disease\n\n          -  Type 1 or 2 diabetes mellitus\n\n          -  Recurrent headaches\n\n          -  Depression, currently receiving treatment (due to possible drug interactions)\n\n          -  Any psychiatric condition or neurological disorder\n\n          -  History of alcohol or drug abuse in the previous 5 years\n\n          -  Ever been diagnosed or told they have or had renal or hepatic dysfunction\n\n          -  Concurrent use of ANY medication taken on a daily basis, to include herbal products\n             or supplements. Daily basis is defined as greater than 2 days per week.\n\n          -  Pregnant or lactating females will be excluded from participation with urine dipstick\n             tests used to confirm pregnancy (pregnancy test performed before each treatment\n             session, days 1 and 8)\n\n          -  All non-English speaking / writing subjects and those that do not understand the\n             study or consent process will be excluded from the study due to unavailability of\n             medical qualified translator at all times during the study.\n\n          -  If the subject refuses to sign the informed consent document or HIPAA Authorization,\n             they will be excluded as well"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "25", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 24, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02023723", 
            "org_study_id": "FDG20130042H"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Monster Energy Drink", 
                    "Active Control"
                ], 
                "description": "16oz Monster Energy drinks - 2 consumed within 60 minutes", 
                "intervention_name": "Monster Energy Drink", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Monster Energy Drink", 
                    "Active Control"
                ], 
                "description": "16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes", 
                "intervention_name": "Active Control", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Energy Drink", 
            "Electrocardiograph", 
            "Hemodynamic"
        ], 
        "lastchanged_date": "December 24, 2013", 
        "location": {
            "contact": {
                "email": "emily.fletcher.1@us.af.mil", 
                "last_name": "Emily Fletcher, PharmD", 
                "phone": "707-423-3068"
            }, 
            "facility": {
                "address": {
                    "city": "Travis AFB", 
                    "country": "United States", 
                    "state": "California", 
                    "zip": "94535"
                }, 
                "name": "David Grant AF Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "Evaluation of Monster Energy\u00ae Drink Consumption on ECG and Hemodynamic Parameters in Young Healthy Volunteers", 
        "overall_contact": {
            "email": "emily.fletcher.1@us.af.mil", 
            "last_name": "Emily Fletcher, PharmD", 
            "phone": "707-423-3068"
        }, 
        "overall_official": {
            "affiliation": "David Grant AF Medical Center", 
            "last_name": "Emily Fletcher, PhamD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "QT/QTc measured on an office ECG", 
            "safety_issue": "Yes", 
            "time_frame": "6 hours over 5 visits"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02023723"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "systolic and diastolic", 
                "measure": "Peripheral Blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "6 hours with 5 visits"
            }, 
            {
                "description": "utilizing an applanation tonometry device", 
                "measure": "Central blood pressure", 
                "safety_issue": "Yes", 
                "time_frame": "6 hours over 5 visits"
            }, 
            {
                "measure": "Augmentation Index, pulse wave", 
                "safety_issue": "Yes", 
                "time_frame": "6 hours over 5 visits"
            }
        ], 
        "source": "David Grant U.S. Air Force Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "David Grant U.S. Air Force Medical Center", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}